Ovarian embryonal carcinoma

Summary

Ovarian embryonal carcinoma (MONDO:0003581) is a cancer and 8 clinical trials. Top therapeutic interventions include bleomycin sulfate, brentuximab vedotin, and cisplatin. A subtype of embryonal carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian embryonal carcinoma
Mondo ID	MONDO:0003581
EFO	EFO:1000415
DOID	DOID:5681
NCIT	C8108
SNOMED CT	254872007
UMLS	C0346183
MedGen	91090
GARD	0023568
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: embryonal carcinoma · embryonal carcinoma of ovary · embryonal carcinoma of the ovary · ovarian embryonal carcinoma · ovary embryonal carcinoma

Data availability: 35 cell lines.

Disease family

This is a subtype of embryonal carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › extragonadal germ cell cancer › extragonadal nonseminomatous germ cell tumor › embryonal carcinoma › ovarian embryonal carcinoma

Related subtypes (3): testicular embryonal carcinoma, non-central nervous system-localized embryonal carcinoma, embryonal carcinoma of the central nervous system

Subtypes (1): childhood ovarian embryonal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cisplatin	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	3
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00053352	PHASE3	COMPLETED	Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT00467051	PHASE2	COMPLETED	Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
NCT02689219	PHASE2	TERMINATED	Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN SULFATE	4	1
BRENTUXIMAB VEDOTIN	4	1
CISPLATIN	4	1